APPLICATION OF COBRA POSTSYNAPTIC NEUROTOXIN IN TREATMENT OF DISEASES RELATED TO INFLAMMATORY CYTOKINE OVEREXPRESSION

摘要

A method for treatment of diseases related to overexpression of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) of a patient in vivo. The method comprises: administering a therapeutically effective dose of cobra postsynaptic neurotoxin molecules (SEQ ID NOs. 1-21) and a pharmaceutically acceptable carrier. The diseases comprise rheumatoid arthritis, rheumatic arthritis, gouty arthritis, osteoarthritis, traumatic arthritis, ankylosing spondylitis, diabetes, diabetic peripheral neuritis, diabetic retinopathy, systemic lupus erythematosus, neuropathic pain, cancer pains, myocarditis, pancreatic cancer, and liver cancer. The mature proteins or peptides of the cobra postsynaptic neurotoxin molecules have any one of the amino acid sequences as shown in SEQ ID NO.1 to SEQ ID NO. 21, or have the homology of 70% or more to the amino acid sequences as shown in SEQ ID NO.1 to SEQ ID NO. 21, respectively.